Who needs to know?
- General practitioners
- Diabetologists
- Diabetes specialist nurses
- People with type 2 diabetes
Results
SGLT-2is and GLP-1RAs provided similar benefits in reducing major adverse cardiovascular event risk when compared to placebo.
SGLT-2is and GLP-1RAs provided similar benefits in reducing major adverse cardiovascular event risk when compared to placebo.